Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Substance Abuse|August 20, 2020
Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorderJermaine D Jones, Aimee N Campbell, Laura Brandt, et al.
The American Journal on Addictions|August 11, 2020
The Increasing Prevalence of Fentanyl: A Urinalysis-Based Study Among Individuals With Opioid Use Disorder in New York CitySuky Martinez, Jermaine D Jones, Laura Brandt, et al.
Pharmacology, Biochemistry, and Behavior|September 8, 2019
Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodoneJermaine D Jones, Mudassir Mumtaz, Jeanne M Manubay, et al.
Pharmacology, Biochemistry, and Behavior|January 11, 2026
Evidence of heterogeneity in the opioid withdrawal syndrome: Spontaneous and precipitated withdrawalSuky Martinez, Jermaine D Jones, Kelly E Dunn, et al.
Journal of Psychoactive Drugs|December 6, 2016
Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use DisorderVerena E Metz, Maria A Sullivan, Jermaine D Jones, et al.
Drug and Alcohol Dependence|June 23, 2012
Assessment of a formulation designed to be crush-resistant in prescription opioid abusersSuzanne K Vosburg, Jermaine D Jones, Jeanne M Manubay, et al.
Drug and Alcohol Dependence|February 23, 2021
Factor structure and psychometric properties of the Connor-Davidson resilience scale (CD-RISC) in individuals with opioid use disorderSuky Martinez, Jermaine D Jones, Laura Brandt, et al.
Addiction (Abingdon, England)|January 16, 2013
A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusersSuzanne K Vosburg, Jermaine D Jones, Jeanne M Manubay, et al.
Pharmacology, Biochemistry, and Behavior|April 26, 2024
The influence of drug class on reward in substance use disordersJermaine D Jones, Caroline A Arout, Rachel Luba, et al.
Physiology & Behavior|October 13, 2015
The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid usersJermaine D Jones, Maria A Sullivan, Jeanne M Manubay, et al.
Pageof 7